{\rtf1 \ansi 
{\colortbl;
\red0\green0\blue0;
\red255\green255\blue255;
\red255\green0\blue0;
\red0\green255\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red255\green0\blue255;
\red255\green255\blue0;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red170\green170\blue170;
\red85\green85\blue85;
\red255\green255\blue174;
\red183\green242\blue206;
\red37\green37\blue37;
\red33\green33\blue33;
\red255\green210\blue183;
\red119\green119\blue119;
\red238\green238\blue238;
\red20\green93\blue164;
\red246\green246\blue246;
\red14\green86\blue140;
\red255\green255\blue102;
\red80\green80\blue80;
\red51\green51\blue51;
\red56\green124\blue43;
\red204\green204\blue204;
\red151\green151\blue151;
\red0\green114\blue54;
\red112\green112\blue112;
\red106\green144\blue39;
\red21\green137\blue21;
\red255\green248\blue96;
\red247\green247\blue247;
\red239\green122\blue2;
\red107\green107\blue106;
\red232\green233\blue232;
\red249\green249\blue249;
\red249\green250\blue251;
\red228\green231\blue232;
\red254\green254\blue0;
\red181\green79\blue104;
\red233\green233\blue233;
\red203\green203\blue203;
\red127\green127\blue127;
\red245\green245\blue245;
\red71\green120\blue194;
\red190\green190\blue252;
\red255\green194\blue211;
\red187\green187\blue187;
\red242\green242\blue242;
\red240\green240\blue240;
\red105\green105\blue105;
\red204\green255\blue255;
\red236\green236\blue236;
\red61\green61\blue61;
\red188\green41\blue30;
\red190\green237\blue228;
\red229\green243\blue255;
\red179\green218\blue255;
\red120\green162\blue47;
\red251\green252\blue255;
\red72\green72\blue72;
\red190\green195\blue204;
\red208\green208\blue208;
\red227\green227\blue227;
\red255\green191\blue101;
\red149\green246\blue220;
\red223\green223\blue223;
\red239\green239\blue239;
\red255\green255\blue198;
\red118\green118\blue118;
\red172\green172\blue172;
\red9\green56\blue84;
\red212\green212\blue212;
\red102\green102\blue102;
\red240\green248\blue255;
}
{\fonttbl {
\f0 Arial;}{
\f1 Symbol;}{
\f2 Times New Roman;}{
\f3 sans-serif;}{
\f4 georgia;}{
\f5 Source Sans Pro;}{
\f6 serif;}
}
{\*\generator Apache XML Graphics RTF Library;}
\fet0 \ftnbj 
{\*\listtable
{\list\listtemplateid-1502316622\listsimple{\listlevel\leveljc\levelfollow0\levelspace0\levelindent0{\leveltext\'01\u160\'3f}{\levelnumbers}}{\listname ;}\listid423434762}
}
{\*\listoverridetable
{\*\listoverride{\listid423434762\listoverridecount0\ls1}}
}
\paperw12240 \paperh15840 \margt1080 \margb1080 \margl1080 \margr1080 \headery720 \footery720 \itap0 \cols2 
\sectd {\header {
{\trowd \ltrrow \trleft0 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrl \trql \clvertalb \clwWidth9380 \cellx9380 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrr \trql \clwWidth700 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
{\b1 \cf18 \f0 \i0 \fs18 
{\b1 \cf18 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
In re BRCA1- and BRCA2-Based Hereditary Cancer Test..., 774 F.3d 755 (2014)
}
}
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 
}\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
113 U.S.P.Q.2d 1241
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \row }}\par }{\footer {
{\trowd \lastrow \trleft0 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrl \trql \clvertalb \clwWidth9300 \cellx9300 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrr \trql \clwWidth700 \cellx10000 
\intbl 
{\b0 \cf17 \f0 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 
}
{\*\shppict {\pict \pngblip \picw78 \pich10 \picwgoal1170 \pichgoal150 89504e470d0a1a0a0000000d494844520000004e0000000a08030000002dbd985500000300504c5445f8a969f6913ff68931fff9f5f69241f5852af68d38fcddc4f58326fac294f8a868fac193fcdabefab985fcdfc7fef5eef58022f8a35efef6effde5d2fac092fffaf6f9ac6ffffcfafde8d7fef7f1f9b279f6862cf8aa6af79e56f79c53f58327fef1e7fde3cefeeee2f9b076f79a4efef8f4f58123f58224f9ae72feefe4f58021f9ae71fac295fffaf7fcdabffef7f2f9af73f9b177f8ac6ef9b47cf8a15bf6872ef79648fef5edf9b278fcd9bdf9b782f9b57efbc89ffde3cffffefdf6872df8aa6bfcd6b8fac59af9b781fabc8bfffbf8fac091fac396fbceaaf8a461f68e39f6882ffabe8dfabf8ff9b884f79c52fdeadbfeede0f68c36f89f58fcdcc3fde0c9fef0e5fef3eaf68f3cfbcaa2f8a867f9b37afaba87f68b35fde7d6fabf90fffcfbfaba86fde7d5f6903efffdfcfef4ecf68f3bfde1cafcdfc6fbd1affbcea9fcd6b7f68a33f79444fbcba5f58429fcdec6f9af74f8a25df58428f7a461fef4edfdede0fde6d4fde7d4f9b680fbc69cfbc8a0f9b37bfac9a1f69240f79d54fcd4b4f9b883f68e3afef8f3fdebddfde2cbf7984cf8a35ff6882efef3ebf9bd8cfcd4b5feecdef8a562fde6d3fef9f4fcdbc1f9bc8afcd8bcf8ab6dfef8f2fcd7b9fffbf7feefe3f79546f8aa69f79f57fde1cbfcd3b3fcd2b1f8a25cfcd3b2fde2ccfac599fac397f9b379fcd8bbfbd2b0fef2e9fcd5b6fac79ef8a664f8a460f68a32fac090fffbf9fef2e8f8ab6cfde4d0f7994df6903df79749fffefcf79e55f8a766f8a059f68830f7974afde2cdfbcca6fabd8cf57f20ffffff000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000c5baaa8e000000bf74524e53ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff00456e8439000002804944415478da63dcc70001fef2931866b0be0cd2085114e5ff7ef72a0357d0a3a31cc2129ebb9f492a3e4b6eb8cb20913bb5c808a2f849bf610c438bf99a9917cf2a18092c7bf1a30a6a0a13946658f6af92e15352e52386af5d677ee5ff61618c5ca7c6b58921d6ecc47383e56a52b3181955bf2e3e01513b49bae7260383be8b048376a2e34786a3853761a6b0c018892b57313c48fa38834195c1cf94c16a3a03c3edad7c5f163030a8672bcc3afcf4251343639ef3ae2cb05afe384e9390352a0c320cbdf71f19b43d6690c7302e84e11383d28bff67bcba9a6e2831acd9c6e0d990fe70b74ae7d2a90c0cbbc36fbaef6660b80f55ba68e9d2d5a9ae0cdd2f341878be8b9c64f8cb701d660a733c9451af78704effa1c6b3536708cf2c9ffde7c78fcb9b16497b8acf3e3721061812bfde8433302c8d5a190152ca93f7d26df6796bff83310dbfe504de7f7ff9ec621c7ad8ade964d5f0f8162da4257e9da18c39434955602283a37fdaefde9cb30c686005c3a4c9a6d792186c6b665d8e54f97ae7c5badd189e65307c22395565fbc43fcc010cad5b3ba781c5363184af0bfa8530481844b84e65b87efde6bcb50c67d9dc36d4f6bf7aa6e4015700771dc3fd57751f183c97ecfe7f04c8b17e9f9fdfceb0e334c3ca37c16940feb644b09ad7e1aee90cdaaa9f1ca31ef6bd6478e2b43ba29f615fc7cf550c1861c720c2699619c930d362d55a060ff68e592f7d4eacd82df9eb3bd7bd387986ff73182d18183686ba2ff9f76ec59f909c2e83a8499dbbaaa404ecf8199cb8051e79627ad6fa4799360383602cd0bdcbdeb2fc6158debec577daf1a9076ba51818e679bf05aaf85cfdeb0f8383c1ec0973801cee342386c537cdf218fecf4b70801b0200f61ff095f54de6170000000049454e44ae426082}}
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
}
}\b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs20 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf17 \f0 \ri0 \i0 \fs20 \li0 
{\b0 \i0 \ul0 \fs20 \f0 \chpgn }
}\qr \b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \fs20 \li0 \intbl \cell \row }}\par }
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_document_9}{\*\bkmkend co_document_9}
{\b0 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart I54d082f5863411e4b86bd602cb8781fa_Target}{\*\bkmkend I54d082f5863411e4b86bd602cb8781fa_Target}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeKC_9}{\*\bkmkend co_readingModeKC_9}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeCitatorFlag_9}{\*\bkmkend co_readingModeCitatorFlag_9}
{\b0 \cf1 \f2 \i0 \fs16 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/RelatedInformation/Flag?documentGuid=I54d082f5863411e4b86bd602cb8781fa&transitionType=Document&originationContext=docHeaderFlag&Rank=0&rs=cblt1.0&vr=3.0&contextData=(sc.Search)" }{\fldrslt 
{\*\shppict {\pict \pngblip \picw16 \pich16 \picwgoal255 \pichgoal255 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}}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
KeyCite Yellow Flag - Negative Treatment
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeNegativeTreatment_9}{\*\bkmkend co_readingModeNegativeTreatment_9}
{\b0 \cf1 \f2 \i0 \fs16 {\fi-360 \li {\*\pn \pnlvlblt \ilvl0 \ls1 \pnindent0 \pnf1 {\f2 \pntxtb \u160\'3f}}{\listtext \b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 \u160\'3f\tab }\ls1 {\pntext }
{\pard }\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Distinguished by 
}
}
{\field {\*\fldinst HYPERLINK "https://www.westlaw.com/Document/I58226150435811e687dda03c2315206d/View/FullText.html?navigationPath=RelatedInfo%2Fv4%2Fkeycite%2Fnav%2F%3Fguid%3DI58226150435811e687dda03c2315206d%26ss%3D2035063513%26ds%3D2039315377%26origDocGuid%3DI54d082f5863411e4b86bd602cb8781fa&listSource=RelatedInfo&list=NegativeCitingReferences&rank=0&ppcid=25ba8d0a9e13498ba250f84a7948bf66&originationContext=docHeader&transitionType=NegativeTreatment&contextData=%28sc.Search%29&VR=3.0&RS=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Rapid Litigation Management Ltd. v. CellzDirect, Inc.
}
{\b0 \cf28 \f2 \i0 \fs16 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
, 
}
}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Fed.Cir.(Ill.), 
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
July 5, 2016
\par {\pntext }
}
}
}
}
}
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
774 F.3d 755
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States Court of Appeals,
\par 
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Federal Circuit.
\par 
}
}
}
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf21 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb240 
In re BRCA1\u8211\'3f and BRCA2\u8211\'3fBASED HEREDITARY CANCER TEST PATENT LITIGATION.
\par 
}
}
}
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf21 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
University of Utah Research Foundation, the Trustees of the University of Pennsylvania, HSC Research and Development Limited Partnership, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5035523639)&saveJuris=False&contentType=BUSINESS-INVESTIGATOR&startIndex=1&contextData=(sc.Default)&categoryPageUrl=Home%2fCompanyInvestigator&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem" }{\fldrslt 
{\b0 \cf28 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
Endorecherche, Inc.
}}}
{\b0 \cf21 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
, and Myriad Genetics, Inc., Plaintiffs\u8211\'3fAppellants,
\par 
}
}
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf21 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
v.
\par 
}
}
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf21 \f4 \ul0 \strike0 \i0 \fs24 \sa240 \sb0 
Ambry Genetics Corporation, Defendant\u8211\'3fAppellee.
\par 
}
}
}
}
{\b0 \qc \cf1 \f2 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Nos. 2014\u8211\'3f1361, 2014\u8211\'3f1366.
\par 
}
}
}
{\b0 \cf1 \f4 \i0 \fs20 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
Dec. 17, 2014.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf22 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_synopsis_9}{\*\bkmkend co_synopsis_9}
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
Synopsis
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Background:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Owners and licensees brought action against clinical diagnostic and genomic services company, alleging infringement of patents for isolated deoxyribonucleic acid (DNA) sequences associated with predisposition to breast cancers and ovarian cancers and for diagnostic methods of identifying mutations in those DNA sequences. Plaintiffs moved for preliminary injunction to enjoin company\rquote s sales or offers to sell genetic tests related to patented DNA sequences pending trial on the merits. The United States District Court for the District of Utah, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0316861901&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Robert J. Shelby
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, J., 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032874428&pubNum=0007903&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
3 F.Supp.3d 1213
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, denied the motion. Plaintiffs appealed.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Holdings:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Court of Appeals, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0127930301&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Dyk
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
, Circuit Judge, held that:
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
claims drawn to pairs of single stranded primers with sequences exclusively derived or isolated from naturally occurring sequences located on specific chromosomes were drawn to subject matter that was not eligible for patent;
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
method claims for comparing patient\rquote s BRCA genetic sequence with wild-type BRCA genetic sequences and identifying any differences that arose were directed to abstract mental process, and thus were not patentable; and
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
claims for particular diagnostic methods to identify mutations in DNA sequences did not render patentable otherwise ineligible abstract mental process method claims.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Affirmed and remanded.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b1 \cf22 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_attorneysAndLawFirms_9}{\*\bkmkend co_attorneysAndLawFirms_9}
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
Attorneys and Law Firms
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_757_9}{\*\bkmkend co_pp_sp_506_757_9}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*757
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0182566101&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Jonathan E. Singer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Fish & Richardson P.C., of Minneapolis, MN, argued for plaintiffs-appellants. With him on the brief were 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0333133901&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Deanna J. Reichel
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0369675901&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Geoff D. Biegler
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, of San Diego, CA. Of counsel on the brief were 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0117376101&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
David G. Mangum
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0187405301&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Michael R. McCarthy
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0214916601&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Kristine E. Johnson
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0157258201&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
C. Kevin Speirs
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Parsons Behle & Latimer, of Salt Lake City, UT.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0321151101&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
William G. Gaede
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, McDermott Will & Emery LLP, of Menlo Park, CA, argued for defendant-appellee. With him on the brief were 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0102799201&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Eric W. Hagen
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and James W. Hill; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0185366501&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
M. Miller Baker
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0408712201&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Daniel K. Greene
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, of Washington, DC, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0355640301&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
John C. Low
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, of Houston, TX.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0326880301&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Sandra S. Park
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, American Civil Liberties Union Foundation of New York, New York for amici curiae. With her on the brief was 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0364917701&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Lenora M. Lapidus
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Of counsel on the brief was 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0319542201&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Barbara Jones
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, AARP Foundation Litigation of Pasadena, CA.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Before 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0324402101&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
PROST
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Chief Judge, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0127928601&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
CLEVENGER
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0127930301&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
DYK
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Circuit Judges.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf22 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_opinion_9}{\*\bkmkend co_opinion_9}
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
Opinion
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifdc418c195fe11ea80afece799150}{\*\bkmkend co_anchor_Ifdc418c195fe11ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0127930301&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
DYK
}}}
\sa200 
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
, Circuit Judge.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifdc418c395fe11ea80afece799150}{\*\bkmkend co_anchor_Ifdc418c395fe11ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Plaintiffs are the University of Utah Research Foundation, The Trustees of the University of Pennsylvania, HSC Research and Development Limited Partnership, Endorecherche, Inc., and Myriad Genetics, Inc. (collectively \u8220\'3fMyriad\u8221\'3f). Myriad owns 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998348225&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ibce1a8d0722911d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 5,753,441 (\u8220\'3fthe \u8242\'3f441 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998357609&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=I8da08b90722e11d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 5,747,282 (\u8220\'3fthe \u8242\'3f282 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998422488&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ia9d8eb20724e11d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 5,837,492 (\u8220\'3fthe \u8242\'3f492 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which cover compositions of matter and methods relating to the BRCA1 and BRCA2 genes. Defendant is Ambry Genetics Corporation (\u8220\'3fAmbry\u8221\'3f), a company that sells medical kits designed to test for the presence of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=I777c6a64995711de9b8c850332338889&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
gene mutations
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 linked to breast and ovarian 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Myriad sought to, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
inter alia,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 enjoin alleged infringement of six claims of three patents: claims 7 and 8 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998348225&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ibce1a8d0722911d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
441 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, claims 16 and 17 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998357609&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=I8da08b90722e11d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 282 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and claims 29 and 30 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998422488&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ia9d8eb20724e11d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
492 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Myriad appeals from a decision of the District Court for the District of Utah denying Myriad\rquote s motion for preliminary injunction. Because we hold that these claims are directed to ineligible subject matter under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, we affirm and remand.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifdc418c495fe11ea80afece799150}{\*\bkmkend co_anchor_Ifdc418c495fe11ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_758_9}{\*\bkmkend co_pp_sp_506_758_9}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*758
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Background
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Supreme Court has addressed some of the patents at issue here in its June 13, 2013, opinion in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Association for Molecular Pathology v. Myriad,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8211\'3f\u8211\'3f\u8211\'3fU.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 133 S.Ct. 2107, 186 L.Ed.2d 124 (2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8221\'3f), as has our court in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2025793527&pubNum=0000506&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Association for Molecular Pathology v. United States Patent and Trademark Office,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 653 F.3d 1329 (Fed.Cir.2011)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
vacated,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8211\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2026688034&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 132 S.Ct. 1794, 182 L.Ed.2d 613 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028417793&pubNum=0000506&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Association for Molecular Pathology v. Myriad,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 689 F.3d 1303 (Fed.Cir.2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
aff\rquote d in part, rev\rquote d in part,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8211\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 133 S.Ct. 2107, 186 L.Ed.2d 124 (2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. This case involves claims of those patents not previously considered by the Supreme Court or by this court. A brief summary of the relevant factual background follows.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In the 1990s, Myriad and its partners discovered the precise locations and sequences of the BRCA1 and BRCA2 genes, mutations of which are linked to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic5e75ac4475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hereditary breast and ovarian cancers
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. By discovering the particular locations and sequences of the genes, Myriad was able to determine the typical sequences of the genes most often found in humans (i.e., the \u8220\'3fwild-type\u8221\'3f sequence for each), as well as mutations, which depart from the two wild-type sequences. Some mutations are harmless, but other mutations are correlated with an increased likelihood of developing particular 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancers
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. By testing for the presence of these mutations, doctors can determine whether the patient is particularly prone to developing breast or ovarian 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Myriad\rquote s efforts to commercialize its discovery through the sale of medical test kits have been successful; to date, Myriad has earned roughly $2 billion in revenue from the sale of the tests.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Supreme Court, in its 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 decision, held that claims of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998357609&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=I8da08b90722e11d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
282 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 directed to isolated DNA were drawn to patent-ineligible subject matter because the isolated DNA strands, which are naturally occurring and separated from the rest of the human genome, were natural phenomena. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_2117&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2117" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 133 S.Ct. at 2117\u8211\'3f19
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Thereafter, generic competitors, including Ambry, entered the market for medical kits designed to test for susceptibility to particular kinds of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
On July 9, 2013, Myriad sued Ambry in the United States District Court for the District of Utah and, on that same day, requested a preliminary injunction. Myriad\rquote s amended complaint alleges infringement of sixty-six claims across fifteen different patents. The preliminary injunction motion asserted, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
inter alia,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the six claims listed above.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00112035063513_ID0E2JAG_9}{\*\bkmkend co_fnRef_B00112035063513_ID0E2JAG_9}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00112035063513_9" }{\fldrslt 
{\super \b0 \cf28 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
On March 10, 2014, the district court denied Myriad\rquote s motion for preliminary injunction. In a detailed, 106\u8211\'3fpage opinion, the court found that Myriad was unlikely to succeed on the merits because the claims were likely drawn to ineligible subject matter, although it found that Myriad would likely suffer irreparable harm from the denial of the injunction and the public interest was in equipoise. The court found that the balance of hardships slightly favored Ambry.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The four composition of matter claims now on appeal are directed to primers, which are \u8220\'3fshort, synthetic, single-stranded DNA molecule[s] that bind [ ] specifically to ... intended target nucleotide sequence[s].\u8221\'3f J.A. 13. The court held these were likely patent ineligible because they claim so-called products of nature\u8212\'3fthat is, 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_759_9}{\*\bkmkend co_pp_sp_506_759_9}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*759
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 they claim the same nucleotide sequence as naturally occurring DNA.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The two method claims now on appeal involve comparisons between the wild-type BRCA sequences with the patient\rquote s BRCA sequences. The court reasoned that these method claims were likely ineligible because \u8220\'3fthe only \u8216\'3finventive concepts\rquote  in the[ ] [m]ethod [c]laims are the patent ineligible naturally occurring BRCA1 and BRCA2 sequences themselves.\u8221\'3f J.A. 93. As found by the district court, \u8220\'3fthe other steps set forth in the method claims are conventional activities that were well-understood and uniformly employed by those working with DNA at the time Myriad applied for its patents....\u8221\'3f J.A. 94.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B12035063513_9}{\*\bkmkend co_anchor_B12035063513_9}
}
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B22035063513_9}{\*\bkmkend co_anchor_B22035063513_9}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 We have jurisdiction pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS1292&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
28 U.S.C. \u167\'3f\u167\'3f 1292
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS1295&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1295
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. We review the district court\rquote s denial of a motion for preliminary injunction for abuse of discretion, but we review legal issues relating to that denial de novo. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018967540&pubNum=0000506&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_506_1375&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1375" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Titan Tire Corp. v. Case New Holland, Inc.,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 566 F.3d 1372, 1375 (Fed.Cir.2009)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2001078952&pubNum=0000506&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_506_1367&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1367" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Globetrotter Software, Inc. v. Elan Computer Grp., Inc.,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 236 F.3d 1363, 1367 (Fed.Cir.2001)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The ultimate question of patent eligibility under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is an issue of law, reviewed de novo. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2026899487&pubNum=0000506&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_506_1333&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1333" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Dealertrack, Inc. v. Huber,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 674 F.3d 1315, 1333 (Fed.Cir.2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifdc418c595fe11ea80afece799150}{\*\bkmkend co_anchor_Ifdc418c595fe11ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Discussion
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifdc418c595fe11ea80afece799150}{\*\bkmkend co_anchor_Ifdc418c595fe11ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb600 
I
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B32035063513_9}{\*\bkmkend co_anchor_B32035063513_9}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 We consider separately the asserted composition of matter claims and the asserted method claims. We address first the composition of matter claims (the \u8220\'3fprimer\u8221\'3f claims). Claim 16 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998357609&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=I8da08b90722e11d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
282 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is representative. It is directed to:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A pair of single-stranded DNA primers for determination of a nucleotide sequence of a BRCA1 gene by a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic0f729ad475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
polymerase chain reaction
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the sequence of said primers being derived from human chromosome 17q, wherein the use of said primers in a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic0f729ad475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
polymerase chain reaction
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 results in the synthesis of DNA having all or part of the sequence of the BRCA1 gene.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998357609&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=I8da08b90722e11d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
282 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 155 ll. 23\u8211\'3f29. Claim 17 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998357609&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=I8da08b90722e11d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
282 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and claims 29 and 30 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998422488&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ia9d8eb20724e11d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
492 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are similar to claim 16 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998357609&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=I8da08b90722e11d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
282 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Our analysis of the primer claims under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is guided by the Supreme Court\rquote s 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 decision. In its 2013 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 decision, the Supreme Court reviewed claims 1, 2, 5, 6, and 7 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998357609&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=I8da08b90722e11d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
282 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, claim 1 of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997377490&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=I0e737f30746811d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 5,693,473
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and claims 1, 6, and 7 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998422488&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ia9d8eb20724e11d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
492 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_2113&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2113" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 133 S.Ct. at 2113 n. 2
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Six of the nine claims covered isolated DNA molecules, which are DNA strands that have been separated from the rest of the human genome. The remaining claims, claims 2 and 7 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998357609&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=I8da08b90722e11d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
282 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and claim 7 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998422488&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ia9d8eb20724e11d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
492 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, covered isolated cDNA molecules, which are synthetically created DNA molecules consisting only of exons\u8212\'3fDNA nucleotides that code for amino acids. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_2111&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2111" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 133 S.Ct. at 2111
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028417793&pubNum=0000506&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_506_1329&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1329" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 689 F.3d at 1329 n. 12
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court held ineligible the isolated DNA claims, explaining: \u8220\'3fMyriad did not create or alter any of the genetic information encoded in the BRCA1 and BRCA2 genes. The location and order of the nucleotides existed in nature before Myriad found them.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_2116&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2116" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 133 S.Ct. at 2116
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Rather, \u8220\'3fMyriad\rquote s principal contribution was uncovering the precise location and genetic sequence of the BRCA [genes].\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Even if Myriad made a \u8220\'3f[g]roundbreaking, innovative, or even brilliant discovery,\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_2117&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2117" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2117
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, that is not enough. With respect to the isolated DNA, \u8220\'3fMyriad did not create anything. To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention.\u8221\'3f 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_760_9}{\*\bkmkend co_pp_sp_506_760_9}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*760
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Court held that \u8220\'3f[g]enes and the information they encode are not patent eligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 simply because they have been isolated from the surrounding genetic material.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_2120&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2120" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2120
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The cDNA claims, however, were held to be patent eligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. cDNA is an exon-only sequence, with no introns, that does not occur in nature, \u8220\'3fexcept insofar as very short series of DNA may have no intervening introns to remove when creating cDNA.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_2119&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2119" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2119
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. To the extent that the exon-only sequence does not exist in nature, the lab technician \u8220\'3funquestionably creates something new when cDNA is made.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The primers before us are not distinguishable from the isolated DNA found patent-ineligible in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and are not similar to the cDNA found to be patent-eligible. Primers necessarily contain the identical sequence of the BRCA sequence directly opposite to the strand to which they are designed to bind. They are structurally identical to the ends of DNA strands found in nature.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Contrary to Myriad\rquote s argument, it makes no difference that the identified gene sequences are synthetically replicated. As the Supreme Court made clear, neither naturally occurring compositions of matter, nor synthetically created compositions that are structurally identical to the naturally occurring compositions, are patent eligible. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2117. After all, as the district court in the earlier 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 case and our opinion in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 made clear, isolated DNA is routinely synthetically created. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2021662409&pubNum=0004637&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_4637_217&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_4637_217" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ass\rquote n for Molecular Pathology v. U.S. Patent and Trademark Office,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 702 F.Supp.2d 181, 217 (S.D.N.Y.2010)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (construing \u8220\'3fisolated DNA\u8221\'3f to \u8220\'3finclude both DNA originating from the cell as well as DNA synthesized through chemical or heterologous biological means\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028417793&pubNum=0000506&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_506_1313&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1313" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 689 F.3d at 1313
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (explaining that \u8220\'3f[i]solated DNA has been cleaved ... or synthesized to consist of just a fraction of a naturally occurring DNA molecule\u8221\'3f and that \u8220\'3fisolated DNA results from human intervention to cleave or synthesize a discrete portion of a native chromosomal DNA\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Myriad argues that primers are in fact not naturally occurring because single-stranded DNA cannot be found in the human body. But, as the Supreme Court made clear, \u8220\'3fseparating [DNA] from its surrounding genetic material is not an act of invention.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_2117&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2117" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 133 S.Ct. at 2117
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Supreme Court held ineligible claims directed to segments as short as 15 nucleotides, the same length as the primer claims at issue here, suggesting that even short strands identical to those found in nature are not patent eligible. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Compare
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998422488&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ia9d8eb20724e11d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 492 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 170 ll. 32\u8211\'3f38, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
with
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998357609&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=I8da08b90722e11d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
282 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 153 ll. 66\u8211\'3f67. This situation is similar to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033340119&pubNum=0000506&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_506_1337&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1337" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In re Roslin Institute (Edinburgh),
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 750 F.3d 1333, 1337 (Fed.Cir.2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. There, we held unpatentable a genetic copy of a naturally occurring organism\u8212\'3fDolly, a cloned sheep\u8212\'3fbecause she \u8220\'3fis an exact genetic replica of another sheep and does not possess \u8216\'3fmarkedly different characteristics from any farm animals found in nature.\u8217\'3f \u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1980116775&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diamond v. Chakrabarty,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 447 U.S. 303, 310, 100 S.Ct. 2204, 65 L.Ed.2d 144 (1980)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) (punctuation omitted).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Myriad also argues that the sequences, when extracted as primers, have a fundamentally different function than when they are part of the DNA strand. When part of the naturally occurring genetic sequence, DNA \u8220\'3fstores the biological information used in the development and functioning of all known living organisms,\u8221\'3f but when isolated as a primer, the DNA fragment \u8220\'3fprime[s], i.e., ... serve[s] as a starting material for a DNA polymerization process.\u8221\'3f Appellants\rquote  Br. 50\u8211\'3f51. In fact, the naturally occurring genetic sequences at 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_761_9}{\*\bkmkend co_pp_sp_506_761_9}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*761
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 issue here do not perform a significantly new function. Rather, the naturally occurring material is used to form the first step in a chain reaction\u8212\'3fa function that is performed because the primer maintains the exact same nucleotide sequence as the relevant portion of the naturally occurring sequence. One of the primary functions of DNA\rquote s structure in nature is that complementary nucleotide sequences bind to each other. It is this same function that is exploited here\u8212\'3fthe primer binds to its complementary nucleotide sequence. Thus, just as in nature, primers utilize the innate ability of DNA to bind to itself.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B42035063513_9}{\*\bkmkend co_anchor_B42035063513_9}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 We do not read the Supreme Court\rquote s opinion in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as conferring patent eligibility on composition of matter claims directed to naturally occurring DNA strands under such circumstances. A DNA structure with a function similar to that found in nature can only be patent eligible as a composition of matter if it has a unique structure, different from anything found in nature. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_2116&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2116" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 133 S.Ct. at 2116\u8211\'3f17
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1980116775&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Chakrabarty,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 447 U.S. at 309\u8211\'3f10, 100 S.Ct. 2204
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Primers do not have such a different structure and are patent ineligible.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifdc418c695fe11ea80afece799150}{\*\bkmkend co_anchor_Ifdc418c695fe11ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifdc418c695fe11ea80afece799150}{\*\bkmkend co_anchor_Ifdc418c695fe11ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb600 
II
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B52035063513_9}{\*\bkmkend co_anchor_B52035063513_9}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 We next address the two asserted method claims, claims 7 and 8 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998348225&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ibce1a8d0722911d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 441 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. While we addressed some of the method claims of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998348225&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ibce1a8d0722911d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
441 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in our 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 decision, the Supreme Court did not address any method claims. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_2119&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2119" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 133 S.Ct. at 2119
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 7, revised to include the language of claim 1, from which it depends, provides:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
A method for screening germline of a human subject for an alteration of a BRCA1 gene which comprises comparing germline sequence of a BRCA1 gene or BRCA1 RNA from a tissue sample from said subject or a sequence of BRCA1 cDNA made from mRNA from said sample with germline sequences of wild-type BRCA1 gene, wild-type BRCA1 RNA or wild-type BRCA1 cDNA, wherein a difference in the sequence of the BRCA1 gene, BRCA1 RNA or BRCA1 cDNA of the subject from wild-type indicates an alteration in the BRCA1 gene in said subject[,]
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
wherein a germline nucleic acid sequence is compared by hybridizing a BRCA1 gene probe which specifically hybridizes to a BRCA1 allele to ge-nomic DNA isolated from said sample and detecting the presence of a hybridization product wherein a presence of said product indicates the presence of said allele in the subject.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998348225&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ibce1a8d0722911d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 441 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 155 ll. 16\u8211\'3f25, 57\u8211\'3f63.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 8, revised to include the language of claim 1, from which it depends, provides:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
A method for screening germline of a human subject for an alteration of a BRCA1 gene which comprises comparing germline sequence of a BRCA1 gene or BRCA1 RNA from a tissue sample from said subject or a sequence of BRCA1 cDNA made from mRNA from said sample with germline sequences of wild-type BRCA1 gene, wild-type BRCA1 RNA or wild-type BRCA1 cDNA, wherein a difference in the sequence of the BRCA1 gene, BRCA1 RNA or BRCA1 cDNA of the subject from wild-type indicates an alteration in the BRCA1 gene in said subject[,]
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
wherein a germline nucleic acid sequence is compared by amplifying all or part of a BRCA1 gene from said sample using a set of primers to produce amplified 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_762_9}{\*\bkmkend co_pp_sp_506_762_9}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*762
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 nucleic acids and sequencing the amplified nucleic acids.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 155 ll. 16\u8211\'3f25, 64\u8211\'3f67.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Ambry argues that the method claims are ineligible under \u8220\'3fa straightforward application\u8221\'3f of the Supreme Court decision in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Services v. Prometheus Laboratories, Inc.,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Appellee\rquote s Br. 44.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the patentee had discovered the relationship between the level of a particular metabolite in a patient\rquote s blood and whether a patient could and should safely be administered additional medication.
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Specifically, 6\u8211\'3fTG metabolite in concentrations in excess of about 400 picomoles per 8x10 
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
8
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 red blood cells risked toxicity, whereas concentrations of less than about 230 picomoles per 8x10 
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
8
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 red blood cells risked ineffectiveness. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_1295&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1295" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 132 S.Ct. at 1295
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The asserted claims taught that doctors should test the metabolite levels of the patient and, if the patient\rquote s metabolite concentration was less than the 230 picomoles floor, the doctor should increase the dosage; if the concentration was greater than the 400 picomoles cap, the doctor should decrease the dosage.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00222035063513_ID0EGUBG_9}{\*\bkmkend co_fnRef_B00222035063513_ID0EGUBG_9}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00222035063513_9" }{\fldrslt 
{\super \b0 \cf28 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The court reiterated that a bare recitation of the natural law was patent ineligible, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_1296&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1296" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1296\u8211\'3f97
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and then went on to consider \u8220\'3fwhether the claims do significantly more than simply describe these natural relations. To put the matter more precisely, do the patent claims add 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
enough
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to their statements of the correlations to allow the processes they describe to qualify as patent-eligible processes that 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
apply
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 natural laws?\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_1297&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1297" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1297
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphases in original).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court found that the additional elements amounted to little more than a broad command to \u8220\'3fapply the law [of nature].\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Focusing on the \u8220\'3fdetermining\u8221\'3f step, the Court explained that \u8220\'3fmethods for determining metabolite levels were well known in the art\u8221\'3f and that \u8220\'3fscientists routinely measured metabolites as part of their investigations into the relationships between metabolite levels and efficacy and toxicity of [the drug].\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1297\u8211\'3f98. Because the additional steps did little more than instruct the practitioners to apply the natural law in routine and conventional ways, the claim was patent ineligible. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1298.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Ambry argues that 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is directly on point because the method claims here, as there, simply identify a law of nature (the precise sequence of the BRCA genes, and comparisons of the wild-type BRCA sequences with certain mutations of those gene sequences found in the test subject) and apply conventional techniques. We need not decide if 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is directly on point here because the method claims before us suffer from a separate infirmity: they recite abstract ideas.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B62035063513_9}{\*\bkmkend co_anchor_B62035063513_9}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Laws of nature are not the only implicit exception to patentable subject matter identified by 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_763_9}{\*\bkmkend co_pp_sp_506_763_9}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*763
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Natural phenomena and abstract ideas are also not patentable. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_2354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2354" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice Corp. v. CLS Bank Int\rquote l,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 134 S.Ct. 2347, 2354, 189 L.Ed.2d 296 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B72035063513_9}{\*\bkmkend co_anchor_B72035063513_9}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Recently in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the Supreme Court reiterated its two-step test to determine patent eligibility for any claims that allegedly encompass abstract ideas. First, \u8220\'3fwe determine whether the claims at issue are directed to [a] patent-ineligible concept[ ]. If so, we then ask, \u8216\'3fwhat else is there in the claims before us?\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_1296&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1296" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 132 S.Ct. at 1296\u8211\'3f97
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) (citations and punctuation omitted). That is, we next ask whether the remaining elements, either in isolation or combination with the other non-patent-ineligible elements, are sufficient to \u8220\'3f \u8216\'3ftransform the nature of the claim\u8217\'3f into a patent-eligible application.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_1297&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1297" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 132 S.Ct. at 1297
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Put another way, there must be a further \u8220\'3finventive concept\u8221\'3f to take the claim into the realm of patent-eligibility. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Here, we treat separately the first paragraphs of claims 7 and 8, which describe the comparison of wild-type genetic sequences with the subject\rquote s genetic sequence and correspond to the first step of 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and the second paragraphs, which describe the techniques to be used in making the comparisons and correspond to the second step of 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We have already addressed the first paragraphs\u8212\'3fthe comparison step\u8212\'3fin our own 2012 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 decision. Claims 7 and 8 at issue here depend from claim 1. Claim 1, which is the first paragraph of claims 7 and 8, is the comparison step.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00332035063513_ID0ESCAI_9}{\*\bkmkend co_fnRef_B00332035063513_ID0ESCAI_9}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00332035063513_9" }{\fldrslt 
{\super \b0 \cf28 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
3
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 In our 2012 decision, we held that claim 1 was patent ineligible because it claimed an abstract mental process of \u8216\'3fcomparing\u8217\'3f and \u8216\'3fanalyzing\u8217\'3f two gene sequences. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028417793&pubNum=0000506&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_506_1334&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1334" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 689 F.3d at 1334
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. We found:
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
[The] claim thus recites nothing more than the abstract mental steps necessary to compare two different nucleotide sequences: one looks at the first position in a first sequence; determines the nucleotide sequence at that first position; looks at the first position in a second sequence; determines the nucleotide sequence at that first position; determines if the nucleotide at the first position in the first sequence and the first position in the second sequence are the same or different, wherein the latter indicates an alteration; and repeats the process for the next position.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Here, under our earlier decision, the comparisons described in the first paragraphs of claims 7 and 8 are directed to the patent-ineligible abstract idea of comparing BRCA sequences and determining the existence of alterations. The methods, directed to identification of alterations of the gene, require merely comparing the patient\rquote s gene with the wild-type and identifying any differences that arise. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998348225&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ibce1a8d0722911d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8242\'3f441 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 155 ll. 16\u8211\'3f25. The number of covered comparisons is unlimited. The covered comparisons are not restricted by the purpose of the comparison or the alteration being detected. Because of its breadth, the comparison step covers detection of yet-undiscovered alterations, as 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_764_9}{\*\bkmkend co_pp_sp_506_764_9}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*764
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 well as comparisons for purposes other than detection of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Even with respect to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the comparisons are not limited to the detection of risk of breast or ovarian 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Similar concerns to the ones the Supreme Court expressed in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 with respect to isolated DNA exist here: allowing a patent on the comparison step could impede a great swath of research relating to the BRCA genes, and it is antithetical to the patent laws to allow these basic building blocks of scientific research to be monopolized. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_2116&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2116" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 133 S.Ct. at 2116
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1972137547&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Gottschalk v. Benson,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 409 U.S. 63, 64, 93 S.Ct. 253, 34 L.Ed.2d 273 (1972)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (holding that a claim on an algorithm for converting binary-coded decimal numbers into pure binary numbers was not patent eligible because \u8220\'3f[t]he claims were not limited to any particular art or technology, to any particular apparatus or machinery, or to any particular end use\u8221\'3f).
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00442035063513_ID0E5IAI_9}{\*\bkmkend co_fnRef_B00442035063513_ID0E5IAI_9}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00442035063513_9" }{\fldrslt 
{\super \b0 \cf28 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
4
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The first paragraphs in claims 7 and 8 are therefore unpatentable abstract ideas, as we held in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B82035063513_9}{\*\bkmkend co_anchor_B82035063513_9}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Having determined that the comparison steps of claims 7 and 8 are abstract ideas, we move to the second step of 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and ask whether the particular mechanism for the comparisons added by claims 7 or 8 renders the claims patent-eligible. For this step, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 dictates that we ask whether the remaining elements, either in isolation or combination with the other non-patent-ineligible elements, are sufficient to \u8220\'3f \u8216\'3ftransform the nature of the claim\u8217\'3f into a patent-eligible application.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 134 S.Ct. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_1297&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1297" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 132 S.Ct. at 1297
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). There must be a further inventive concept to take the claim into the realm of patent-eligibility. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The second paragraph of claim 7 describes the way in which the sequences are compared: they are compared by 1) hybridizing a BRCA gene probe and 2) detecting the presence of a hybridization product.
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Similarly, claim 8 requires 1) amplification of the BRCA1 gene and 2) sequencing of the amplified nucleic acids.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The non-patent-ineligible elements of claims 7 and 8 do not add \u8220\'3fenough\u8221\'3f to make the claims as a whole patent-eligible. The district court found, and Myriad does not challenge, that the elements of the second paragraphs of claims 7 and 8 \u8220\'3fset forth well-understood, routine and conventional activity engaged in by scientists at the time of Myriad\rquote s patent applications.\u8221\'3f J.A. 93 (internal capitalization removed). Moreover, \u8220\'3f[a]ny scientist engaged in obtaining the sequence of a gene in a patient sample would rely on these techniques.\u8221\'3f J.A. 95. Myriad does not challenge the district court\rquote s finding that \u8220\'3fthe claims contain no otherwise new process for designing or using probes, primers, or arrays beyond the use of BRCA1 and BRCA2 sequences in those processes.\u8221\'3f Appellants\rquote  Rep. Br. 5 (quoting J.A. 93\u8211\'3f94) (alterations omitted). The second paragraphs of claims 7 and 8 do nothing more than spell out what practitioners already knew\u8212\'3fhow to compare gene sequences using routine, ordinary techniques. Nothing is added by identifying the techniques to be used in making the comparison because those comparison techniques were the well-understood, routine, and conventional techniques that a scientist would have thought of when instructed to compare two gene sequences.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Myriad argues that these claims should be patent eligible because they are similar to claim 21 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998348225&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ibce1a8d0722911d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
441 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which Judge Bryson suggested was patent eligible in his separate opinion in our 2012 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_765_9}{\*\bkmkend co_pp_sp_506_765_9}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*765
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028417793&pubNum=0000506&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_506_1349&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1349" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 decision. 
}
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 689 F.3d at 1349
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. There, Judge Bryson indicated that, \u8220\'3f[a]s the first party with knowledge of the sequences, Myriad was in an excellent position to claim applications of that knowledge. Many of its unchallenged claims are limited to such applications.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028417793&pubNum=0000506&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_506_1349&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1349" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 689 F.3d at 1349
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (Bryson, J., concurring in part and dissenting in part) (citing claims found in the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998348225&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ibce1a8d0722911d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 441 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998422488&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ia9d8eb20724e11d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
492 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998357609&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=I8da08b90722e11d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
282 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). The Supreme Court approved of Judge Bryson\rquote s general suggestion, directly quoting him for the propositions that \u8220\'3f[a]s the first party with knowledge of the BRCA1 and BRCA2 sequences, Myriad was in an excellent position to claim applications of that knowledge,\u8221\'3f and that \u8220\'3f[m]any of its unchallenged claims are limited to such applications.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_2120&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2120" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad,
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 133 S.Ct. at 2120
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. But, nowhere in the opinion did the Court express approval of the individual claims identified by Judge Bryson, much less of claim 21 in particular. Indeed, no method claim was even before the Supreme Court. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=RP&fi=co_pp_sp_708_2119&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2119" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2119
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Even if claim 21 of the \u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998348225&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ibce1a8d0722911d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
441 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 were patent eligible\u8212\'3fa question about which we express no view\u8212\'3fclaim 21 is qualitatively different from the method claims at issue here. Claim 21 claims a method of detecting alterations in which the alterations being detected are expressly identified in the specification by tables 11 and 12.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00552035063513_ID0EUUAI_9}{\*\bkmkend co_fnRef_B00552035063513_ID0EUUAI_9}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00552035063513_9" }{\fldrslt 
{\super \b0 \cf28 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
5
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 These tables expressly identify ten predisposing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib0dd2702475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
mutations of the BRCA1 gene
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 sequence discovered by the patentees. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998348225&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ibce1a8d0722911d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8242\'3f441 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 157 ll. 11\u8211\'3f17, col. 56 ll. 50\u8211\'3f59, col. 60 ll. 7\u8211\'3f18. Thus, the detection in claim 21 is limited to the particular mutations the inventors discovered: detecting ten specific mutations from the wild-type, identified as \u8220\'3f[p]redisposing [m]utations,\u8221\'3f for the specific purpose of identifying increased susceptibility to specific 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancers
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998348225&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ibce1a8d0722911d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8242\'3f441 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 60 ll. 8\u8211\'3f19. Claims 7 and 8 are significantly broader and more abstract, as they claim all comparisons between the patient\rquote s BRCA genes and the wild-type BRCA genes.
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998348225&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ibce1a8d0722911d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8242\'3f441 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 155 ll. 16\u8211\'3f63. The first paragraphs of claims 7 and 8, as we held in our 2012 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 opinion, claim abstract comparisons. We hold today that the second paragraphs recite only routine and conventional steps. The claims, therefore, are directed to patent-ineligible subject matter.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifdc418c795fe11ea80afece799150}{\*\bkmkend co_anchor_Ifdc418c795fe11ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Conclusion
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The claims on appeal are directed to ineligible subject matter in violation of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Therefore, the district court properly denied Myriad\rquote s motion for preliminary injunction. We remand to the district court for an entry of an order consistent with this opinion.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifdc418c895fe11ea80afece799150}{\*\bkmkend co_anchor_Ifdc418c895fe11ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifdc418c895fe11ea80afece799150}{\*\bkmkend co_anchor_Ifdc418c895fe11ea80afece799150}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb600 
AFFIRMED AND REMANDED
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Costs
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Costs to appellee.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf22 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_allCitations_9}{\*\bkmkend co_allCitations_9}
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
All Citations
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
774 F.3d 755, 113 U.S.P.Q.2d 1241
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \ltrrow \trleft0 
\clpadl200 \clpadfl3 \clbrdrt \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf1 \f3 \i0 \fs20 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Footnotes
\par 
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \ql \li0 \fs20 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00112035063513_9}{\*\bkmkend co_footnote_B00112035063513_9}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00112035063513_ID0E2JAG_9" }{\fldrslt 
{\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Myriad originally sought to enjoin infringement of four additional claims: claims 2 and 4 of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997388863&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=I2e24e9a0746c11d7a94bace56a9eba1c&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
U.S. Patent No. 5,654,155 (\u8220\'3fthe \u8242\'3f 155 patent\u8221\'3f)
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, claim 5 of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2007425893&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Iae112a2635ee11da8cc9b4c14e983401&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
U.S. Patent No. 6,951,721 (\u8220\'3fthe \u8242\'3f721 patent\u8221\'3f)
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, and claim 4 of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2000348614&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ifd36f5d071f611d796fabc35f7796f7a&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
U.S. Patent No. 6,033,857 (\u8220\'3fthe \u8242\'3f857 patent\u8221\'3f)
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. Myriad no longer pursues those claims as grounds for the preliminary injunction.
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00222035063513_9}{\*\bkmkend co_footnote_B00222035063513_9}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00222035063513_ID0EGUBG_9" }{\fldrslt 
{\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
2
}\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The patent claimed:
\par 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li180 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
A method of optimizing therapeutic efficacy for treatment of an immune-mediated gastrointestinal disorder, comprising:
\par 
}
}
}
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li180 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
(a) administering a drug providing 6\u8212\'3fthioguanine to a subject having said immune-mediated gastrointestinal disorder; and
\par 
}
}
}
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li180 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
(b) determining the level of 6\u8212\'3fthioguanine in said subject having said immune-mediated gastrointestinal disorder,
\par 
}
}
}
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li180 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
wherein the level of 6\u8212\'3fthioguanine less than about 230 pmol per 8x10 
}
{\b0 \cf1 \f3 \i0 \fs13 
{\super \b0 \cf1 \f3 \ul0 \strike0 \i0 \fs13 \sa0 \sb0 
8
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 red blood cells indicates a need to increase the amount of said drug subsequently administered to said subject and
\par 
}
}
}
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li180 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
wherein the level of 6\u8211\'3fthioguanine greater than about 400 pmol per 8x10 
}
{\b0 \cf1 \f3 \i0 \fs13 
{\super \b0 \cf1 \f3 \ul0 \strike0 \i0 \fs13 \sa0 \sb0 
8
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 red blood cells indicates a need to decrease the amount of said drug subsequently administered to said subject.
\par 
}
}
}
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002176446&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=I175c6f3071fc11d7ab54daa4035d65fa&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
U.S. Patent No. 6,355,623
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 col. 20 ll. 10\u8211\'3f20.
\par 
}
}
}
}
}
}\b0 \cf1 \f3 \strike0 \i0 \fs18 \sa0 \sb0 \super \ri0 \ul0 \qj \li0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00332035063513_9}{\*\bkmkend co_footnote_B00332035063513_9}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00332035063513_ID0ESCAI_9" }{\fldrslt 
{\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
3
}\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Claim 1 reads as follows:
\par 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li180 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
A method for screening germline of a human subject for an alteration of a BRCA1 gene which comprises comparing germline sequence of a BRCA1 gene or BRCA1 RNA from a tissue sample from said subject or a sequence of BRCA1 cDNA made from mRNA from said sample with germline sequences of wild-type BRCA1 gene, wild-type BRCA1 RNA or wild-type BRCA1 cDNA, wherein a difference in the sequence of the BRCA1 gene, BRCA1 RNA or BRCA1 cDNA of the subject from wild-type indicates an alteration in the BRCA1 gene in said subject.
\par 
}
}
}
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998348225&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ibce1a8d0722911d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
441 patent
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, col. 155 ll. 15\u8211\'3f25.
\par 
}
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00442035063513_9}{\*\bkmkend co_footnote_B00442035063513_9}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00442035063513_ID0E5IAI_9" }{\fldrslt 
{\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
4
}\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The preemptive nature of the claims is not ameliorated even if we accept Myriad\rquote s argument that other methods of comparison exist. If the combination of certain routine steps were patent eligible, so too would different combinations of other routine steps.
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrb \clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00552035063513_9}{\*\bkmkend co_footnote_B00552035063513_9}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00552035063513_ID0EUUAI_9" }{\fldrslt 
{\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
5
}\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Claim 21 (revised to include the language of claim 20, from which it depends) provides:
\par 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li180 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
A method for detecting a germline alteration in a BRCA1 gene, said alteration selected from the group consisting of the alterations set forth in Tables 11 and 12 which comprises analyzing a sequence of the BRCA1 gene or BRCA1 RNA from a human sample or analyzing the sequence of BRCA1 CDNA made from mRNA from said sample[,]
\par 
}
}
}
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li180 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
wherein a germline alteration is detected by hybridizing a BRCA1 gene probe which specifically hybridizes to an allele of one of said alterations to RNA isolated from said human sample and detecting the presence of a hybridization product, wherein the presence of said product indicates the presence of said allele in the sample.
\par 
}
}
}
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8242\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1998348225&pubNum=0004074&originatingDoc=I54d082f5863411e4b86bd602cb8781fa&refType=PA&docFamilyGuid=Ibce1a8d0722911d7a07084608af77b15&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
441 patent
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 col. 157 ll. 11\u8211\'3f24.
\par 
}
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt24 \clpadft3 \clpadl100 \clpadfl3 \clpadr24 \clpadfr3 \clbrdrt \brdrcf24 \brdrw10 \brdrs \clbrdrb \clbrdrl \trql \clvertalt \clwWidth4320 \cellx4320 
\clpadt29 \clpadft3 \clpadl100 \clpadfl3 \clpadr29 \clpadfr3 \clbrdrt \brdrcf24 \brdrw10 \brdrs \clbrdrb \clbrdrr \trql \clvertalt \clwWidth5760 \cellx10080 
\intbl 
{\ri24 \li24 
{\b1 \cf24 \f3 \ri24 \i0 \ql \fs16 \li24 
{\b1 \cf24 \f3 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
End of Document
\par 
}
}
}\b1 \cf24 \f3 \ri24 \ul0 \strike0 \i0 \ql \li24 \fs16 \sa0 \sb0 \intbl \cell \intbl 
{\ri29 \li29 
{\qr \b0 \cf24 \f3 \ri29 \i0 \fs19 \li29 
{\b0 \cf24 \f3 \ul0 \strike0 \i0 \fs19 \sa0 \sb0 
\u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
\par 
}
}
}\qr \b0 \cf24 \f3 \ri29 \ul0 \strike0 \i0 \li29 \fs19 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}\sect }